DLBCL
MCID: DFF005
MIFTS: 56

Diffuse Large B-Cell Lymphoma (DLBCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Diffuse Large B-Cell Lymphoma

MalaCards integrated aliases for Diffuse Large B-Cell Lymphoma:

Name: Diffuse Large B-Cell Lymphoma 12 52 58 15 37 17 71 32
Dlbcl 52 58
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified 71
Large B-Cell Diffuse Lymphoma 74

Characteristics:

Orphanet epidemiological data:

58
diffuse large b-cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (France); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0050745
ICD10 32 C83.3
MESH via Orphanet 44 D016403
ICD10 via Orphanet 33 C83.3
UMLS via Orphanet 72 C0079744
Orphanet 58 ORPHA544
UMLS 71 C0079744 C2699777

Summaries for Diffuse Large B-Cell Lymphoma

NIH Rare Diseases : 52 Diffuse large B-cell lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common blood cancer . Lymphomas occur when cells of the immune system , known as B lymphocytes , grow and multiply uncontrollably. DLBCL occurs mostly in adults and is a fast-growing (aggressive) lymphoma. It can start in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes , thyroid, skin, breast, bone, or brain. Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. For some people, the swelling may be painful. Other symptoms include night sweats, unexplained fevers, and weight loss. Treatment may differ depending on the location of the tumor and the subtype of lymphoma. For those who have advanced DCBCL and have not been treated previously, a combination of chemotherapy and the monoclonal antibody rituximab (Rituxan) (R-CHOP ) may be tried. . In addition, as of October 2017, axicabtagene ciloleucel (brand name: Yescarta), a type of gene therapy , has been approved by the United States FDA to treat DCBCL that is not responding to at least two treatment attempts or has returned after being treated before. A stem cell transplant may also be an option if DLBCL returns or relapses.

MalaCards based summary : Diffuse Large B-Cell Lymphoma, also known as dlbcl, is related to b-cell lymphoma and follicular lymphoma. An important gene associated with Diffuse Large B-Cell Lymphoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways are DNA Damage Response and MicroRNAs in cancer. The drugs Decitabine and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Disease Ontology : 12 A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.

Wikipedia : 74 Diffuse large B-cell lymphoma is a cancer of B cells, a type of white blood cell responsible for... more...

Related Diseases for Diffuse Large B-Cell Lymphoma

Diseases related to Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 804)
# Related Disease Score Top Affiliating Genes
1 b-cell lymphoma 33.5 MIR21 MIR17HG MIR17 MIR155 HOTAIR
2 follicular lymphoma 33.2 MIR210 MIR17 MIR155
3 lymphoma, non-hodgkin, familial 32.3 MIR21 MIR17HG MIR17 MIR155 MIR151A
4 burkitt lymphoma 31.8 MIR21 MIR17HG MIR155 MIR145 MIR143 MIR127
5 myeloma, multiple 31.0 MIR21 MIR17 MIR155 HOTAIR
6 thyroid cancer, nonmedullary, 1 30.9 MIR221 HULC HOTAIR
7 leukemia, chronic lymphocytic 30.9 PEG10 MIR221 MIR21 MIR17HG MIR17 MIR155
8 rectum cancer 30.8 MIR21 MIR17 MIR145 MIR143
9 leukemia, acute lymphoblastic 30.7 MIR221 MIR210 MIR21 MIR17 MIR155 MIR151A
10 leukemia, chronic myeloid 30.7 MIR17 MIR155 MIR151A MIR10A HULC HOTAIR
11 dermatomyositis 30.7 MIR221 MIR210 MIR21 MIR155
12 leukemia, acute myeloid 30.7 MIR221 MIR210 MIR21 MIR17 MIR155 MIR151A
13 central nervous system disease 30.7 MIR221 MIR21 MIR17 MIR155 MIR151A MIR10A
14 nasopharyngeal carcinoma 30.6 MIR21 MIR17 MIR151A MIR143 HULC HOTAIR
15 acute t cell leukemia 30.5 MIR17 MIR151A LUNAR1
16 polymyositis 30.4 MIR221 MIR210 MIR21 MIR155 MIR127
17 thyroid gland papillary carcinoma 30.4 MIR221 MIR210 MIR17 MIR151A MIR127
18 gallbladder disease 30.3 MIR17 MIR145 MIR143
19 pancreatic adenocarcinoma 30.3 MIR221 MIR210 MIR21 MIR155 MIR145
20 nervous system disease 30.3 MIR221 MIR21 MIR17 MIR155 MIR151A MIR145
21 esophageal cancer 30.2 PEG10 MIR21 MIR155 MIR145 MIR143 HULC
22 renal cell carcinoma, nonpapillary 29.8 PANDAR MIR221 MIR210 MIR21 MIR17 MIR155
23 large intestine cancer 29.8 MIR221 MIR21 MIR17 MIR155 MIR151A MIR145
24 intestinal disease 29.8 MIR221 MIR21 MIR17 MIR155 MIR151A MIR145
25 gastrointestinal system disease 29.8 MIR221 MIR21 MIR17 MIR155 MIR151A MIR145
26 arteries, anomalies of 29.8 MIR221 MIR210 MIR21 MIR17 MIR155 MIR145
27 connective tissue disease 29.7 MIR221 MIR210 MIR21 MIR17 MIR155 MIR151A
28 bladder cancer 29.7 PANDAR MIR221 MIR21 MIR17 MIR145 MIR143
29 gastric cancer 29.6 PANDAR MIR221 MIR21 MIR17 MIR145 MIR143
30 prostate cancer 29.4 MIR221 MIR210 MIR21 MIR17 MIR151A MIR145
31 ovarian cancer 29.0 MIR221 MIR210 MIR21 MIR17 MIR155 MIR145
32 relapsed/refractory diffuse large b-cell lymphoma 13.0
33 primary cutaneous diffuse large b-cell lymphoma, leg type 13.0
34 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 12.9
35 diffuse large b-cell lymphoma of the central nervous system 12.9
36 diffuse large b-cell lymphoma with chronic inflammation 12.9
37 gray zone lymphoma 12.4
38 primary central nervous system lymphoma 12.1
39 t-cell/histiocyte rich large b cell lymphoma 12.1
40 reticulosarcoma 12.0
41 primary mediastinal b-cell lymphoma 11.9
42 richter's syndrome 11.9
43 mediastinal gray zone lymphoma 11.7
44 lymphoma 11.6
45 plasmablastic lymphoma 11.4
46 primary mediastinal large b-cell lymphoma 11.4
47 intravascular large b-cell lymphoma 11.3
48 lymphoma, hodgkin, classic 11.3
49 alk-positive large b-cell lymphoma 11.2
50 neutropenia 11.0

Graphical network of the top 20 diseases related to Diffuse Large B-Cell Lymphoma:



Diseases related to Diffuse Large B-Cell Lymphoma

Symptoms & Phenotypes for Diffuse Large B-Cell Lymphoma

Drugs & Therapeutics for Diffuse Large B-Cell Lymphoma

Drugs for Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 320)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
2
Epirubicin Approved Phase 4 56420-45-2 41867
3
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
4 Endothelial Growth Factors Phase 4
5
Apatinib Phase 4 811803-05-1
6
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
7
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
8
Mesna Approved, Investigational Phase 3 3375-50-6 598
9
Vinblastine Approved Phase 3 865-21-4 13342 241903
10
Iodine Approved, Investigational Phase 3 7553-56-2 807
11
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
12
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
13
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
14
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1
15
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
16
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
17
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
18
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
19
rituximab Approved Phase 3 174722-31-7 10201696
20
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
21
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
22
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
23
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
24
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
25
Bevacizumab Approved, Investigational Phase 3 216974-75-3
26
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
28
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
29
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
30
Emodepside Investigational, Vet_approved Phase 2, Phase 3 155030-63-0
31 Anti-Bacterial Agents Phase 3
32 Alkylating Agents Phase 3
33 Antibiotics, Antitubercular Phase 3
34 Hormone Antagonists Phase 3
35 Topoisomerase Inhibitors Phase 3
36 Anti-Inflammatory Agents Phase 3
37 Antineoplastic Agents, Hormonal Phase 3
38 Immunosuppressive Agents Phase 3
39 glucocorticoids Phase 3
40 Hormones Phase 3
41 Immunologic Factors Phase 3
42 Antipyretics Phase 3
43 cadexomer iodine Phase 3
44 Iodine-131 anti-B1 antibody Phase 3
45 Antimitotic Agents Phase 3
46 Antibodies, Monoclonal Phase 3
47 Immunoglobulins Phase 3
48 Antibodies Phase 3
49 Micronutrients Phase 3
50 Trace Elements Phase 3

Interventional clinical trials:

(show top 50) (show all 915)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
3 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
4 Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma. Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
5 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03579082 Phase 4 Decitabine
6 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Recruiting NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
7 Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma Recruiting NCT04152577 Phase 4 R2-combination chemotherapy;R-combination chemotherapy
8 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
9 Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study Unknown status NCT02777736 Phase 3 Methotrexate
10 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
11 R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail Unknown status NCT00846157 Phase 3
12 A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL) Unknown status NCT02867566 Phase 3 IBI301 plus CHOP;Rituximab plus CHOP
13 A Phase Ⅲ, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients Unknown status NCT02772822 Phase 3 SCT400 plus CHOP;Rituximab plus CHOP
14 A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma Unknown status NCT03151044 Phase 3 High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
15 Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
16 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
17 A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells. Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
18 Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma Unknown status NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
19 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
20 A Phase III, Open-Label, Prospective, Two-Armed, Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study Regimen Versus Observation in Patients With Diffuse Large B-Cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
21 High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial Unknown status NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
22 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
23 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
24 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
25 Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide
26 A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
27 A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
28 Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1. Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide
29 A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01148446 Phase 3 Cyclophosphamide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Prednisone;Epirubicin;Vinblastine;Rituximab;G-CSF
30 Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma. Completed NCT00144755 Phase 3 Darbepoetin alfa
31 A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Completed NCT00332202 Phase 3 enzastaurin;placebo
32 Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma. Completed NCT01987505 Phase 3 Rituximab
33 A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT01649856 Phase 3 CHOP;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
34 An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL Completed NCT01459887 Phase 3 CHOP combined with CMAB304;CHOP, CMAB304
35 A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Completed NCT01197560 Phase 2, Phase 3 Lenalidomide;Gemcitabine;Oxaliplatin;Rituximab;Etoposide
36 A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line Completed NCT02268045 Phase 3
37 Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas Completed NCT00355199 Phase 3 Rituximab-HDS;Rituximab-CHOP
38 Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab Completed NCT00137995 Phase 3 Rituximab;Etoposide;Carboplatine;Ifosfamide + Mesna;Cisplatine;Cytosine Arabinoside;Dexamethasone;BCNU;Etoposide;Cytarabine;Melphalan
39 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
40 A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed NCT01889069 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
41 A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
42 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01014208 Phase 3 OFATUMUMAB + DHAP;RITUXIMAB + DHAP
43 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma Completed NCT00491491 Phase 3 ibritumomab tiuxetan
44 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
45 A Rand. Trial Comp Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine, and Prednisone) in Patients With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment Completed NCT00774202 Phase 2, Phase 3 Rituxan, Cyclophosphamide, Vincristine, Prednisone;Higher Dose of Rituximab
46 Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN #0401) Completed NCT00329030 Phase 3 Autologous transplantation using rituxan/BEAM;Autologous transplantation using Bexxar/BEAM
47 Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL Completed NCT02787239 Phase 3 HLX01;Rituximab;CHOP
48 A Phase III, Open-Label, Multicenter, Randomized, Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Recruiting NCT04182204 Phase 3 Polatuzumab Vedotin;Rituximab;Gemcitabine;Oxaliplatin
49 Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study Recruiting NCT02428751 Phase 3 Pegylated liposomal doxorubicin;Doxorubicin;Rituximab;Cyclophophamide;Vincristine;Prednisone
50 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™ Recruiting NCT03263026 Phase 3 Enzastaurin Hydrochloride

Search NIH Clinical Center for Diffuse Large B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diffuse Large B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Diffuse Large B-Cell Lymphoma

Anatomical Context for Diffuse Large B-Cell Lymphoma

MalaCards organs/tissues related to Diffuse Large B-Cell Lymphoma:

40
B Cells, T Cells, Bone, Bone Marrow, Breast, Thyroid, Liver

Publications for Diffuse Large B-Cell Lymphoma

Articles related to Diffuse Large B-Cell Lymphoma:

(show top 50) (show all 12353)
# Title Authors PMID Year
1
Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. 61 46
19287466 2009
2
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. 61 46
18537969 2008
3
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. 61 46
18318758 2008
4
MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. 61 46
17487835 2007
5
BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. 61 46
16041695 2005
6
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. 61 46
15738415 2005
7
Downregulation of microRNAs-143 and -145 in B-cell malignancies. 46
17892514 2007
8
MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. 46
16675453 2006
9
Chemoimmunotherapy for localised low-risk diffuse large B-cell lymphoma. 61
31868615 2020
10
Effect of Plasma-Derived Exosomes of Refractory/Relapsed or Responsive Patients with Diffuse Large B-Cell Lymphoma on Natural Killer Cells Functions. 61
31606965 2020
11
Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches. 61
31725418 2020
12
Czech and Slovak Diamond-Blackfan Anemia (DBA) Registry update: Clinical data and novel causative genetic lesions. 61
31855845 2020
13
Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren's syndrome patients: case series study and review of the literature. 61
31707561 2020
14
Follicular lymphoma: 2020 update on diagnosis and management. 61
31814159 2020
15
Extranodal involvement of multiple organs in diffuse large B cell lymphoma detected on 18F-FDG PET/CT. 61
31915898 2020
16
Rapid and sustained response to Chimeric Antigen Receptor T cell therapy in double hit diffuse large B cell lymphoma. 61
31429117 2020
17
Immunological microenvironment gene expression in patients with diffuse large B cell non Hodgkin lymphoma. 61
32025577 2020
18
An Uncommon Initial Presentation of T-Cell/Histiocyte-Rich B-Cell Lymphoma: Acute Renal Failure. 61
31876835 2020
19
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials. 61
31988978 2020
20
Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma. 61
31804739 2020
21
Challenges in Assessing MYC Rearrangement in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. 61
31764222 2020
22
Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease. 61
31533509 2020
23
Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients With Richter Syndrome. 61
31876819 2020
24
Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study. 61
32031030 2020
25
HISTOLOGIC FINDINGS IN VITREORETINAL LYMPHOMA: Learning From Enucleation Specimens. 61
31972811 2020
26
Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015. 61
31884334 2020
27
Pulmonary Intravascular Large B-cell Lymphoma in a Patient Administered Methotrexate for Rheumatoid Arthritis. 61
31619597 2020
28
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. 61
31530861 2020
29
Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art. 61
31486520 2020
30
Development of Primary Diffuse Large B-cell Lymphoma around an Internal Fixation Implant after Lumbar Fusion Surgery: A Case Report and Review of the Literature. 61
32035201 2020
31
Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study. 61
31688139 2020
32
Diffuse large B cell lymphoma-derived extracellular vesicles educate macrophages to promote tumours progression by increasing PGC-1β. 61
31833575 2020
33
Multiple cytokine-producing aggressive EBV-positive diffuse large B cell lymphoma, not otherwise specified with hemophagocytic syndrome. 61
31768673 2020
34
Epstein-Barr virus-positive diffuse large B cell lymphoma, not otherwise specified, carrying a t(19;22)(q13;q11) translocation. 61
31848683 2020
35
Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma. 61
31669174 2020
36
β-elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway. 61
32010942 2020
37
Sciatic pain by neurolymphomatosis as initial presentation of disseminated diffuse large B cell lymphoma involving the testis and the CNS. 61
32026488 2020
38
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. 61
32030731 2020
39
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma. 61
32025840 2020
40
A Rare Case of Primary Ventricular Lymphoma Presented on FDG PET/CT. 61
31833937 2020
41
Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. 61
31752540 2020
42
Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine. 61
31350718 2020
43
[Value of Red Blood Cell Distribution Width and Fibrinogen Level for Evaluation of the Therapeutic Efficacy and Prognosis in Patients with Diffuse Large B-Cell Lymphoma]. 61
32027269 2020
44
High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey. 61
31732878 2020
45
Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience. 61
31674036 2020
46
TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods. 61
31932115 2020
47
Lymphoma Recurrence Along the Lymphatic Tract on 18F-FDG PET/CT Presenting as Lower Limb Swelling. 61
31876814 2020
48
A Huge Primary Cardiac Malignant Lymphoma in the Left Ventricle. 61
32035915 2020
49
The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02. 61
31555945 2020
50
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). 61
31541205 2020

Variations for Diffuse Large B-Cell Lymphoma

Cosmic variations for Diffuse Large B-Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM93183630 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.743G>A p.R248Q 17:7674220-7674220 0

Copy number variations for Diffuse Large B-Cell Lymphoma from CNVD:

7 (show top 50) (show all 118)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13828 1 1 84900000 Loss Diffuse large b-cell lymphoma
2 17406 1 142600000 249250621 Gain Diffuse large b-cell lymphoma
3 20082 1 15300000 163800000 Gain Diffuse large b-cell lymphoma
4 38345 10 101900000 103000000 Gain Diffuse large b-cell lymphoma
5 38773 10 104900000 105800000 Gain Diffuse large b-cell lymphoma
6 38901 10 105800000 121700000 Loss Diffuse large b-cell lymphoma
7 40597 10 130600000 135534747 Loss Diffuse large b-cell lymphoma
8 43294 10 46100000 64500000 Loss Diffuse large b-cell lymphoma
9 48479 11 1 43500000 Gain Diffuse large b-cell lymphoma
10 51204 11 123900000 135006516 Loss Diffuse large b-cell lymphoma
11 53206 11 26100000 36400000 Loss Diffuse large b-cell lymphoma
12 55792 11 55700000 135006516 Gain Diffuse large b-cell lymphoma
13 64291 12 12600000 14800000 Gain CDKN1B Diffuse large b-cell lymphoma
14 70914 12 66000000 69800000 Gain MDM2 Diffuse large b-cell lymphoma
15 74343 13 104800000 110300000 Loss Diffuse large b-cell lymphoma
16 74383 13 105800000 109100000 Loss Diffuse large b-cell lymphoma
17 75387 13 19500000 55300000 Gain Diffuse large b-cell lymphoma
18 76712 13 35500000 75400000 Loss Diffuse large b-cell lymphoma
19 79280 13 68600000 115169878 Gain Diffuse large b-cell lymphoma
20 86223 14 55800000 61200000 Loss Diffuse large b-cell lymphoma
21 88116 14 84900000 107349540 Loss Diffuse large b-cell lymphoma
22 90236 15 20700000 102531392 Loss Diffuse large b-cell lymphoma
23 97251 16 1 34600000 Gain Diffuse large b-cell lymphoma
24 97373 16 1 7900000 Gain ABCA3 Diffuse large b-cell lymphoma
25 97375 16 1 7900000 Gain DCI Diffuse large b-cell lymphoma
26 97377 16 1 7900000 Gain E4F1 Diffuse large b-cell lymphoma
27 97379 16 1 7900000 Gain HAGH Diffuse large b-cell lymphoma
28 97381 16 1 7900000 Gain IGFALS Diffuse large b-cell lymphoma
29 97383 16 1 7900000 Gain MRPS34 Diffuse large b-cell lymphoma
30 97385 16 1 7900000 Gain NME3 Diffuse large b-cell lymphoma
31 97387 16 1 7900000 Gain NUBP2 Diffuse large b-cell lymphoma
32 97391 16 1 7900000 Gain RNPS1 Diffuse large b-cell lymphoma
33 99692 16 28100000 36600000 Loss Diffuse large b-cell lymphoma
34 102840 16 57400000 90354753 Gain Diffuse large b-cell lymphoma
35 102843 16 57400000 90354753 Loss Diffuse large b-cell lymphoma
36 104071 16 66700000 70800000 Gain DDX19 Diffuse large b-cell lymphoma
37 104073 16 66700000 70800000 Gain FUK Diffuse large b-cell lymphoma
38 104075 16 66700000 70800000 Gain SIAT4B Diffuse large b-cell lymphoma
39 106530 16 88700000 90354753 Gain Diffuse large b-cell lymphoma
40 106806 17 1 22200000 Loss Diffuse large b-cell lymphoma
41 111431 17 3600000 6800000 Loss TP53 Diffuse large b-cell lymphoma
42 120634 18 2900000 78077248 Gain Diffuse large b-cell lymphoma
43 121454 18 43500000 48200000 Gain Diffuse large b-cell lymphoma
44 121719 18 46400000 52000000 Gain BCL2 Diffuse large b-cell lymphoma
45 122173 18 53800000 56200000 Gain MALT1 Diffuse large b-cell lymphoma
46 123098 18 66800000 68700000 Loss Diffuse large b-cell lymphoma
47 123108 18 66900000 71300000 Gain Diffuse large b-cell lymphoma
48 127687 19 35500000 38300000 Gain KIRREL2 Diffuse large b-cell lymphoma
49 127689 19 35500000 38300000 Gain MLL4 Diffuse large b-cell lymphoma
50 127691 19 35500000 38300000 Gain NPHS1 Diffuse large b-cell lymphoma

Expression for Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Diffuse Large B-Cell Lymphoma.

Pathways for Diffuse Large B-Cell Lymphoma

Pathways related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.93 MIR221 MIR210 MIR17HG MIR17
2 11.72 MIR221 MIR210 MIR21 MIR17 MIR155 MIR145
3 11.18 MIR17HG MIR17 MIR127 MIR10A
4 11.03 MIR221 MIR210 MIR145

GO Terms for Diffuse Large B-Cell Lymphoma

Cellular components related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 MIR221 MIR210 MIR21 MIR17 MIR155 MIR151A

Biological processes related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.69 MIR221 MIR21 MIR17
2 positive regulation of blood vessel endothelial cell migration GO:0043536 9.67 MIR221 MIR210 MIR143
3 negative regulation of angiogenesis GO:0016525 9.67 MIR21 MIR145 MIR143 MIR10A
4 positive regulation of activated T cell proliferation GO:0042104 9.64 MIR21 MIR155
5 positive regulation of cardiac muscle hypertrophy GO:0010613 9.63 MIR21 MIR155
6 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.63 MIR221 MIR155
7 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.62 MIR21 MIR17
8 negative regulation of necroptotic process GO:0060546 9.62 MIR221 MIR155
9 negative regulation of cardiac muscle hypertrophy GO:0010614 9.61 MIR21 MIR145
10 regulation of smooth muscle contraction GO:0006940 9.61 MIR145 MIR143
11 negative regulation of innate immune response GO:0045824 9.6 MIR21 MIR155
12 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.59 MIR17 MIR155
13 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.58 MIR17 MIR155
14 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR17 MIR155
15 positive regulation of metalloendopeptidase activity GO:1904685 9.57 MIR21 MIR17
16 negative regulation by host of viral genome replication GO:0044828 9.56 MIR221 MIR155
17 angiotensin-activated signaling pathway GO:0038166 9.55 MIR145 MIR143
18 negative regulation of regulatory T cell differentiation GO:0045590 9.54 MIR21 MIR155
19 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.52 MIR221 MIR155
20 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.5 MIR221 MIR21 MIR143
21 aorta smooth muscle tissue morphogenesis GO:0060414 9.48 MIR145 MIR143
22 regulation of phenotypic switching GO:1900239 9.46 MIR145 MIR143
23 negative regulation of cell adhesion molecule production GO:0060354 9.43 MIR221 MIR155
24 miRNA mediated inhibition of translation GO:0035278 9.43 MIR221 MIR210 MIR21 MIR17 MIR155 MIR145
25 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.4 MIR17 MIR143
26 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.33 MIR210 MIR21 MIR17
27 gene silencing by miRNA GO:0035195 9.28 MIR221 MIR210 MIR21 MIR17HG MIR17 MIR155
28 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.26 MIR145 MIR143

Molecular functions related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR221 MIR210 MIR21 MIR17HG MIR17 MIR155

Sources for Diffuse Large B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....